BACKGROUND There is a lack of studies and educational programs focused on biosimilars
and shared decision-making among patients diagnosed with various rheumatic diseases …

Objectives We sought to evaluate perceptions of biosimilar products among US
rheumatologists who prescribe TNF-α inhibitors, given that 10 TNF-α inhibitor biosimilars …

Objectives To assess rheumatologist perception towards biosimilars and the likelihood of
use of biosimilars to manage RA patients in the EU, Brazil, Japan and China. Methods A …

Objectives To assess the relationship between duration of rheumatology practice
experience and rheumatologist perception towards biosimilars and the likelihood of use of …

Patient perceptions influence biosimilar uptake in non-mandatory transitions. Companions
(support people) are often actively involved in the patient's medical journey and are likely to …

Rising biologic drug costs pose serious, ongoing threats to the health and financial well-
being of people with rheumatic diseases in many areas of the world. As drug costs have …

Abstract Background/Aims With an increasing number of biologic and targeted synthetic
disease-modifying anti-rheumatic drugs and their biosimilar agents coming to the market …

Background Healthcare cost savings are closely linked to prescribers' confidence in and
acceptance of the prescription of biosimilar drugs. Objectives The aim of this study was to …

BACKGROUND: By the end of 2023, 10 self-administered biosimilars indicated for
autoimmune conditions are expected to launch in the United States, resulting in alternative …

Abstract In May 2019, the Government of British Columbia (BC) announced the
implementation of the Biosimilars Initiative, mandating the switch of biologic (originator) …